Eli Lilly is a ‘play’ in type 2 diabetes and obesity: Sam Waksal
Graviton Biopharmaceuticals Holdings CEO Sam Waksal argues there will be ‘great growth’ in the pharmaceutical industry.
Pharmaceutical giant Novo Nordisk will lower the cost of several of its insulin products by up to 75% next year.
Effective January 2024, the list price for insulin brands, including NovoLog and NovoLog Mix 70/30, will be reduced by 75%, the company announced Tuesday. The list price for Novolin and Levemir will be reduced by 65%.
The company also pledged to lower the price of unbranded insulin products to match the lower price of each respective branded insulin. This change will also take effect in January 2024.
ELI LILLY CAPS OUT-OF-POCKET COSTS FOR INSULIN EFFECTIVE IMMEDIATELY
More than 37 million Americans are living with diabetes, and 8.4 million Americans rely on insulin to survive, according to the American Diabetes Association. Insulin costs are typically 10 times higher in the U.S. than anywhere else in the world, the association said.